Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
Frese
A
A
Bethke
F
F
Lüdemann
P
P
Stögbauer
F
F
D000328:Adult; D001323:Autoantibodies; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009157:Myasthenia Gravis / Q000139:chemically induced*; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate